A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Massachusetts General Hospital
Wuhan Ammunition Life-tech Co., Ltd
Shanghai Gopherwood Biotech Co., Ltd.
Beijing Immunochina Medical Science & Technology Co., Ltd.
Critical Outcome Technologies Inc.
Merrimack Pharmaceuticals
AHS Cancer Control Alberta
National Cancer Institute (NCI)